Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Rallybio names Lieber Chief Financial Officer

Rallybio reports that Jonathan I. Lieber has joined the company as Chief Financial Officer, effective February 1. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio’s Co-Founder and...

| By Kelley Gipson

Science Park planning new housing, lab space

With several key approvals in recent weeks, plans to redevelop sections of the former Winchester firearms factory at New Haven’s Science Park are moving forward with a...

| By Kelley Gipson

Biopharma key part of CT workforce development

Connecticut Governor Ned Lamont has made workforce development a key issue going into his second term, and his two-year, $50.5 billion budget proposal sets aside tens of millions...

| By Kelley Gipson

Halda reports positive results re prostate cancer

New Haven biotech company Halda Therapeutics reports positive results in preclinical trials of its oral candidate for the treatment of prostate cancer. Halda is developing a novel...

| By Kelley Gipson

Cara pruritus treatment shows potential

Cara Therapeutics reports that the New England Journal of Medicine (NEJM) has published results from the KOMFORT Phase 2 clinical trial of oral difelikefalin in...

| By Kelley Gipson

The Roundup – February 16, 2023

View this email in your browser February 16, 2023 Women in Bio – Boardroom Ready Application, March 15, 2023 The Boardroom Ready platform is rooted...

| By Kelley Gipson

UConn looks at cannabis, coronary catheterization

UConn School of Medicine Assistant Professor of Immunology Zhichao Fan is leading groundbreaking research into the novel use of a leukocyte-inhibiting drug to reduce tissue damage...

| By Kelley Gipson

BioXcel reports positive data from Phase 2 trial

BioXcel Therapeutics is reporting full data from its Phase 2a trial of BXCL701, the Company’s investigational, oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in...

| By Kelley Gipson

Abryx to open operations in Stamford

The biotechnology company Abryx has announced that it will open a manufacturing and distribution operation in Stamford, CT. It will lease 7,000 square feet of space and plans...

| By Kelley Gipson

$200K Bioscience Scholarship Fund launched

More than two dozen New Haven city officials and local public-education leaders gathered in the library of Career High School at 140 Legion Ave. to...